Biologics & Advanced Therapies
Biotech medicines, cell and gene therapies, tissue and blood products — biological manufacturing and its viral-safety and characterisation demands.
What this page does not claim
SPEQ decodes published standards and does not determine which apply to your product. An industry’s counts measure SPEQ’s coverage, not the size of its rulebook.
WHAT THIS INDUSTRY COVERS
Biologics & Advanced Therapies spans biotech medicines (monoclonal antibodies, recombinant proteins, vaccines), cell and gene therapies, and human tissue and blood products. These are manufactured from living systems, so quality turns on characterisation, viral safety, and control of an inherently variable biological process — a step up in complexity from small molecules.
REGULATORY LANDSCAPE
Governed by FDA (CBER; 21 CFR 210/211 plus 1271 for HCT/Ps and 606 for blood), EU GMP Annex 2 for biological products, and the ICH Q5-series (viral safety, stability, comparability) and Q6B. Advanced therapies add cell/gene-specific expectations, and comparability after process change is a defining regulatory theme.
WHAT TO DO FIRST
- TOOLKITAnnex 1 CCS Implementation Toolkit →Build the contamination control strategy that aseptic manufacture rests on.
- HOW-TO GUIDEHow to Perform a Technology Transfer →Move a process between development and manufacturing without losing what was learned.
- TOOLBacterial Endotoxin Limit Calculator →Work out an endotoxin limit from dose and route before release testing begins.
WHY THIS PRODUCT IS HARD TO CONTROL
The process defines the product, and that is not a slogan — it is the reason biologics are regulated under a separate statute. A monoclonal antibody or a cell therapy is produced by a living system whose output varies with conditions no specification fully captures: glycosylation patterns, aggregate profiles, host-cell impurities. Two batches meeting the same release specification can differ in ways the specification was never designed to see, which is why a process change triggers a comparability exercise rather than a re-test, and why the manufacturing history is part of the product’s identity in a way it is not for a small molecule.
WHAT QUALITY MEANS HERE
Viral safety & contaminant control
Testing cell lines and raw materials, and demonstrating the process clears or inactivates virus (ICH Q5A) — the safety backbone of any cell-line-derived product.
Characterisation & comparability
Defining the product’s quality attributes and proving comparability after any process or site change, since the process largely defines the product.
Aseptic & cold-chain control
Sterile drug-substance and drug-product handling plus the cold chain that protects labile biologics from manufacture to patient.
Cell, gene & tissue-specific controls
Donor eligibility, chain-of-identity/custody, and the HCT/P and blood-product controls unique to living therapeutics.
STANDARDS SPEQ DECODES · 97
Open the full library →WHERE QUALITY FAILS
- Adventitious agent or bioburden contamination of the process
- Loss of comparability after a process or scale change
- Chain-of-identity or chain-of-custody breaks in cell/gene therapy
- Cold-chain excursions degrading a labile product
GXP DISCIPLINES IN THIS INDUSTRY
Biologics & Advanced Therapies: frequently asked questions
Quick answers to common questions about GxP in Biologics & Advanced Therapies.
How are biologics regulated differently from small-molecule drugs?
Because biologics are made from living systems, quality turns on characterisation, viral safety, and comparability rather than a fixed chemical synthesis. They are governed by FDA CBER (21 CFR 210/211 plus 1271 for HCT/Ps and 606 for blood), EU GMP Annex 2, and the ICH Q5-series and Q6B.
What is comparability in biologics manufacturing?
Comparability is the evidence that a product’s quality attributes are maintained after a process, scale, or site change. Because the process largely defines a biologic, regulators expect a comparability exercise for changes that a small-molecule product would not require.
What is viral safety in biologics, and which guideline covers it?
Viral safety is demonstrated under ICH Q5A by testing cell lines and raw materials and by showing the manufacturing process clears or inactivates virus across complementary, orthogonal steps. It is the safety backbone of any cell-line-derived product.
PUT IT TO WORK
- HOW-TO GUIDEHow to Stand Up a Regulated Operating Model →Build the quality system a new regulated company actually needs — in the order that makes each next step possible.
- HOW-TO GUIDEHow to Run One Site for Several GMP Regulators →Meet the shared GMP standard once and each market’s legal differences on top, so any of the site’s regulators can inspect it on any day.
- ASSESSBaseline your quality system →Twelve GxP domains, about ten minutes, free with an account.
A free account keeps what you save, remembers where you are across devices, and can send you the weekly regulatory briefing. Create a free account